CDRH’s Shuren: FDA’s 510(k) findings due soon

Dr. Jeffrey Shuren, head of the Food & Drug Administration’s medical device oversight arm, told a Massachusetts audience that results from the agency’s internal, soup-to-nuts review of its 510(k) clearance program are due out in a few weeks.

At the second in a series of "town hall" meetings in Woburn, Mass., the Center for Devices & Radiological Health’s leader said the federal watchdog would seek public comment on the report before making any changes to the program.

Shuren told MassDevice that the agency still hasn’t decided exactly what changes are in store for the 510(k) process.

"What we’ve been saying so far is not anything about what changes we’re going to make. There’s a lot of rumor mill about what we’re going to do, but we’ve not said we’re doing A, B, C or D specifically," he told us. "The only thing I’m very clear about is we’re not recommending to get rid of the 510(k) program."

Asked if the Obama administration is advocating for more stringent oversight of medical devices, Shuren said his department has been given free rein to police the industry as it sees fit.

"I have had absolutely no pressure or pushback from the administration. Even the commissioner of FDA, has, I think much to her credit, let the center do its own assessment, come back with its own recommendations," Shuren said. "I can tell you the things that we want to put out for the public have her full support in moving forward."

The FDA’s internal 520(k) review includes the feedback generated at the town hall meetings, Shuren said, as well as examinations of the agency’s database and a survey of its review staff and managers.

"I think one of the challenges for both industry and FDA on the 510(k) is that there have not been tools — very good metrics — put in place to access the effectiveness of the program. That’s something that needs to be addressed in the future. There’s been a lot of discussion, for example, of, "Well, we’re not seeing a lot of people dying across the country from medical devices on the market," he said. "Well, actually, people do get hurt by medical devices, but on the flip side no device is risk-free. The question is, were these anticipated risks and have we taken appropriate steps to mitigate to the extent we can? Nothing is going to be risk free.

Jeffrey Shuren

CDRH head Dr. Jeffrey Shuren

"The real test of the program is whether or not, when we’re making a decision for a device to go on the market, there are truly reasonable assurances of safety and effectiveness. That’s what the standard is — not whether a device made it on the market and it turned out to be unsafe," Shuren said. "The FDA is there to check to make sure it’s safe and effective before it goes on the market. It’s either safe and effective or it’s not before it’s coming to us. The same with medical devices. And that’s the real test of the 510(k) program and how it’s implemented. Is it good enough and are we implementing in a way that when a device gets on the market there truly are reasonable assurances of safety and effectiveness?"

To that end, he said, some companies applying for 510(k) clearance will be asked to submit more clinical data than in the past.

"Those decisions are case-by-case, based on the device. What we will try to address is, can we be more clear about when we would anticipate clinical data for a device?" Shuren told us.

Touching on the high-profile controversy over the FDA’s clearance of ReGen Biologics Inc.’s (OTC:RGBO) Menaflex knee cartilage implant, Shuren said that foofaraw wasn’t behind the scrutiny of the 510(k) protocol.

"A lot of people have asked did we do this over ReGen. The answer is no," he said "These issues we uncovered in 510(k) were circling around for a while."

Citing the programs origins in 1976, Shuren said the agency has tried over the years to adapt it as a path to market for lower-risk medical devices.

"FDA has tried to be flexible to squeeze through as many devices as possible, [but] as technology evolves it’s not as adequate," he said. "It’s not the first time we’ve done [a review] and it probably won’t be the last time. The world will change and we have to make appropriate mid-point adjustments."

In his opening remarks, Shuren said the message from the medical device industry has been consistent on one subject: The need for predictability along the regulatory pathway.

"I have heard a clear message from you: The FDA needs to provide industry with clear, predictable pathways to approval and clearance. We hear you. We agree. And we’re on it," Shuren said. "Providing clear, predictable pathways to market will also help foster innovation, which is the other theme we’ve been hearing. We agree with you on this front, as well."

To that end, he said, the agency is putting "concrete step we can take to be a smarter FDAs" into its strategic priorities for 2010.

"One such step is to make available our experts to help industry solve problems, not just identify them," Shuren explained. "For example, we’ve been collaborating with the University of Pennsylvania on open-source software for external infusion pumps that manufacturers can build on or use to benchmark their own products. In fact, we’ve offered to perform diagnostics on infusion pump software at any stage of development — even before the device lands at our doorstep."

More than 500 people attended Shuren’s first town hall meeting May 18 in Minneapolis, he said, noting that a scheduled town hall meeting in Los Angeles in October would be his last this year.

RSS From Medical Design & Outsourcing

  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]
  • Sigma-Aldrich announces a new certification to aid IVD customers
    Sigma-Aldrich, a life science and high technology company, announced the company has received ISO 13485 certification for expanded quality assurance capabilities at its Dekalb and Barton facilities located in St. Louis. The certification extends Sigma-Aldrich’s ability to manufacture and offer critical raw materials, such as enzymes, proteins and antibodies used in diagnostic assays, and supplies in vitro […]
  • Prescribing the right power supply: Important considerations for using batteries to power medical devices
    Sol Jacobs, VP and General Manager, Tadiran Batteries Medical technology is advancing rapidly, requiring increasingly sophisticated power management solutions, especially when then the device needs to be self-powered. Battery-powered medical devices encompass a wide range of applications, including surgical drills, power tools, automatic external defibrillators (AEDs), infusion pumps, bone growth stimulators and other wearable devices, […]
  • Qosina announces the launch of its e-commerce website
    Qosina is pleased to announce the launch of its e-commerce website, making it easier to purchase thousands of medical device components from stock inventory. Visitors coming to the new will discover a new look and feel and improvements with every click including: · Easy navigation: A new category structure that mirrors the print catalog […]
  • Athermal laser machining for medical implants is the topic of Norman Noble’s latest whitepaper
    Thermal lasers have achieved extraordinary results in microprecision manufacturing of medical implants and devices the past 20 years. Devices we take for granted today, such as vascular stents, could not be produced without the technology; however, there are still significant limitations on what medical implant and device manufactures can produce using thermal lasers. One major issue […]
  • Sealevel announces the SeaISO family of USB isolators
    Sealevel announces the SeaISO family of USB isolators with 4 kV of medical-grade optical isolation between the host computer and connected USB equipment. SeaISO USB isolators are UL Recognized, in accordance with EN60601-1 3rd Edition, and protect both the power and data lines of connected USB devices from harmful ground loops, damaging transients and surges […]
  • The 21st Century Cures Discussion document recently released to the public
    It has been reported that among the 10,000 known diseases, 7,000 of which are considered rare, there are treatments for only 500. According to Dr. Francis Collins, Director of the National Institutes of Health (NIH), it now takes “around 14 years and $2 billion or more” to develop a new drug and “more than 95% […]

Leave a Reply